Skip to main content

Advertisement

Table 2 Baseline characteristics and studied parameters of the four groups along with statistical comparison

From: Low molecular weight heparins use in pregnancy: a practice survey from Greece and a review of the literature

 Group A N = 76Group B N = 445Group C N = 132Group D N = 165p-value*
Age (mean ± SD)33.0 ± 4.333.5 ± 4.637.2 ± 5.132.5 ± 4.4<.0001
BMI (mean, SD)25.0 ± 4.324.4 ± 3.924.7 ± 3.824.4 ± 4.30.2607
No. of foetuses at the observed gestation (N. %)
 173, 96.1%434, 97.5%102, 77.3%158, 95.8%<.0001
  ≥ 23, 4.0%11, 2.5%30, 22.7%7, 4.2%
Mean Duration of LMWH (months)8.7 ± 1.78.7 ± 1.38.7 ± 1.78.3 ± 1.6<.0001
ASA Duration (months) (N of patients)6.7 ± 2.8 (N = 11)6.1 ± 2.4 (N = 79)5.5 ± 2.8 (N = 39)7.9 ± 2.0 (N = 19)0.0068
Fixed Prophylactic Dose34.2%58.9%50%52.1%<.0001
Weight Adjusted prophylactic dose21.1%32.4%38.6%37.0%
Therapeutic dose of LMWH44.7%8.8%11.4%10.9%
Concomitant Use of ASA14.5%18.2%30.3%12.1%0.0006
Caesarian80.3%79.7%91.7%65.5%<.0001
Live Birth97.4%99.1%97.0%99.4%0.1632
High risk Thrombophilia (positive cases)25%10.1%9.9%10.3%0.0018
APA status (total successful tests N = 363) (% positive cases within group)29.6%29.1%27.1%20.4%0.6264
  1. *p-value is for Kruskal-Wallis test for numerical parameters and for x-square test for categorical parameters